DK1866338T3 - Antistoffer mod cd38 til behandling af myelomatose - Google Patents

Antistoffer mod cd38 til behandling af myelomatose

Info

Publication number
DK1866338T3
DK1866338T3 DK06722861.9T DK06722861T DK1866338T3 DK 1866338 T3 DK1866338 T3 DK 1866338T3 DK 06722861 T DK06722861 T DK 06722861T DK 1866338 T3 DK1866338 T3 DK 1866338T3
Authority
DK
Denmark
Prior art keywords
myeloma
treatment
antibodies against
antibodies
Prior art date
Application number
DK06722861.9T
Other languages
Danish (da)
English (en)
Inventor
Michel De Weers
Yvo Graus
Judith Oprins
Jan Van De Winkel
Martine Van Vugt
Paul Parren
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Priority claimed from PCT/DK2006/000166 external-priority patent/WO2006099875A1/en
Application granted granted Critical
Publication of DK1866338T3 publication Critical patent/DK1866338T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK06722861.9T 2005-03-23 2006-03-23 Antistoffer mod cd38 til behandling af myelomatose DK1866338T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US69616305P 2005-07-01 2005-07-01
US72856105P 2005-10-20 2005-10-20
PCT/DK2006/000166 WO2006099875A1 (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
DK1866338T3 true DK1866338T3 (da) 2017-01-02

Family

ID=50644285

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06722861.9T DK1866338T3 (da) 2005-03-23 2006-03-23 Antistoffer mod cd38 til behandling af myelomatose

Country Status (12)

Country Link
KR (1) KR20140033240A (cg-RX-API-DMAC7.html)
BE (1) BE2017C062I2 (cg-RX-API-DMAC7.html)
DK (1) DK1866338T3 (cg-RX-API-DMAC7.html)
ES (2) ES2644982T3 (cg-RX-API-DMAC7.html)
HU (2) HUE030783T2 (cg-RX-API-DMAC7.html)
LT (2) LT1866338T (cg-RX-API-DMAC7.html)
NZ (2) NZ600059A (cg-RX-API-DMAC7.html)
PL (1) PL1866338T3 (cg-RX-API-DMAC7.html)
PT (2) PT2567976T (cg-RX-API-DMAC7.html)
RS (1) RS55442B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201610317VA (cg-RX-API-DMAC7.html)
UA (2) UA116520C2 (cg-RX-API-DMAC7.html)

Also Published As

Publication number Publication date
ES2606762T3 (es) 2017-03-27
KR20140033240A (ko) 2014-03-17
RS55442B1 (sr) 2017-04-28
LT2567976T (lt) 2017-12-11
PT1866338T (pt) 2016-12-14
HUE030783T2 (en) 2017-06-28
HUE034962T2 (en) 2018-03-28
NZ625944A (en) 2016-01-29
ES2644982T3 (es) 2017-12-01
PT2567976T (pt) 2017-10-19
BE2017C062I2 (cg-RX-API-DMAC7.html) 2025-12-03
UA116520C2 (uk) 2018-04-10
PL1866338T3 (pl) 2017-04-28
UA98756C2 (ru) 2012-06-25
SG10201610317VA (en) 2017-02-27
LT1866338T (lt) 2017-01-25
NZ600059A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
DK3421498T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2178863T3 (da) Fremgangsmåde til syntetisering af anvendelige forbindelser til behandling af hepatitis C
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK3199180T3 (da) Epha3-antistoffer til behandlingen af faste tumorer
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
IL243687A0 (en) For the treatment of multiple myeloma 1–cs antibodies against
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
DK1866338T3 (da) Antistoffer mod cd38 til behandling af myelomatose
DK1937662T3 (da) Fremgangsmåde til fremstilling af duloxetin
DK2121649T3 (da) Fremgangsmåde til fremstilling af benzofuran-2-carboxamider
DK1833814T3 (da) Fremgangsmåde til fremstilling af substituerede 2-alkoxycarbonyl-3-aminothiophener
HUS1700054I1 (hu) CD38-ellenes antitestek a mielóma multiplex kezelésére